Dogwood is pioneering Halneuron®, a highly selective sodium channel blocker being developed to treat moderate-to-severe chemotherapy induced neuropathic pain (CINP), cancer pain, and other pain indications. It is also developing the antiviral combination therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID (“LC”) and fibromyalgia (“FM”)
Company Details
- Employees
- 7
- Founded
- -
- Address
- 44 Milton Avenue, Alpharetta,georgia 30009,united States
- Industry
- Biotechnology
- Website
- https://dwtx.com
- HQ
- Alpharetta, Georgia
Dogwood Therapeutics Questions
Dogwood Therapeutics's website is https://dwtx.com
Dogwood Therapeutics's LinkedIn profile is https://www.linkedin.com/company/dogwoodther
Dogwood Therapeutics has
7 employees.
View email and phone details for 7
employees at Dogwood Therapeutics.
Dogwood Therapeutics's industry is
Biotechnology
Dogwood Therapeutics's top competitors are
Neurolixis,
Marvel Biosciences Corp.,
60 Degrees Pharmaceuticals, Inc,
Alpha Cognition, Inc.,
Maxona Pharmaceuticals,
Dyne Therapeutics,
Kariya Pharmaceuticals,
Grin Therapeutics, Inc.,
Prilenia,
Wex Pharmaceuticals Inc..
Dogwood Therapeutics's categories are Biotechnology
Dogwood Therapeutics's founding year is 2020
